deltatrials
Active Not Recruiting PHASE2 INTERVENTIONAL 1-arm NCT04103879

US Study of UM171-Expanded CB in Patients With High Risk Leukemia/Myelodysplasia

A Phase II Open-Label Study of UM171-Expanded Cord Blood Transplantation in Patients With High and Very High Risk Acute Leukemia/Myelodysplasia

Sponsor: ExCellThera inc.

Conditions Cord Blood Transplant High Risk Hematological Malignancy
Interventions ECT-001-CB (UM171-Expanded Cord Blood Transplant)
Updated 13 times since 2019 Last updated: Feb 24, 2025 Started: Nov 13, 2020 Primary completion: Feb 28, 2026 Completion: Feb 28, 2026
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT04103879, this PHASE2 trial focuses on Cord Blood Transplant and High Risk Hematological Malignancy and remains ongoing. Sponsored by ExCellThera inc., it has been updated 13 times since 2020, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

~Oct 2019 – ~Feb 2020 · 4 months · monthly snapshot~Feb 2020 – ~Nov 2020 · 9 months · monthly snapshot~Nov 2020 – ~Jan 2021 · 2 months · monthly snapshot~Jan 2021 – ~Feb 2022 · 13 months · monthly snapshot~Feb 2022 – ~May 2022 · 3 months · monthly snapshot~May 2022 – ~Feb 2023 · 9 months · monthly snapshot~Feb 2023 – ~Jul 2023 · 5 months · monthly snapshot~Jul 2023 – ~Oct 2023 · 3 months · monthly snapshot~Oct 2023 – ~Mar 2024 · 5 months · monthly snapshot~Mar 2024 – ~Jul 2024 · 4 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Mar 2025 · 6 months · monthly snapshot~Mar 2025 – present · 18 months · monthly snapshot

Change History

13 versions recorded

  1. Mar 2025 — Present [monthly]

    Active Not Recruiting PHASE2

  2. Sep 2024 — Mar 2025 [monthly]

    Active Not Recruiting PHASE2

  3. Jul 2024 — Sep 2024 [monthly]

    Active Not Recruiting PHASE2

  4. Mar 2024 — Jul 2024 [monthly]

    Active Not Recruiting PHASE2

    Status: Recruiting → Active Not Recruiting

  5. Oct 2023 — Mar 2024 [monthly]

    Recruiting PHASE2

▶ Show 8 earlier versions

  1. Jul 2023 — Oct 2023 [monthly]

    Recruiting PHASE2

  2. Feb 2023 — Jul 2023 [monthly]

    Recruiting PHASE2

  3. May 2022 — Feb 2023 [monthly]

    Recruiting PHASE2

  4. Feb 2022 — May 2022 [monthly]

    Recruiting PHASE2

  5. Jan 2021 — Feb 2022 [monthly]

    Recruiting PHASE2

  6. Nov 2020 — Jan 2021 [monthly]

    Recruiting PHASE2

  7. Feb 2020 — Nov 2020 [monthly]

    Recruiting PHASE2

  8. Oct 2019 — Feb 2020 [monthly]

    Recruiting PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • ExCellThera inc.
  • Fred Hutchinson Cancer Center
Data source: ExCellThera inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations